Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 360.00
GLPGF's Cash to Debt is ranked higher than
76% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GLPGF: 360.00 )
GLPGF' s 10-Year Cash to Debt Range
Min: 6.63   Max: No Debt
Current: 360

Equity to Asset 0.58
GLPGF's Equity to Asset is ranked higher than
68% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GLPGF: 0.58 )
GLPGF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.77
Current: 0.58

0.5
0.77
F-Score: 5
Z-Score: 2.30
M-Score: -5.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -20.26
GLPGF's Operating margin (%) is ranked higher than
80% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. GLPGF: -20.26 )
GLPGF' s 10-Year Operating margin (%) Range
Min: -59.16   Max: 1.78
Current: -20.26

-59.16
1.78
Net-margin (%) 50.75
GLPGF's Net-margin (%) is ranked higher than
97% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. GLPGF: 50.75 )
GLPGF' s 10-Year Net-margin (%) Range
Min: -58.19   Max: 3.57
Current: 50.75

-58.19
3.57
ROE (%) 28.47
GLPGF's ROE (%) is ranked higher than
97% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. GLPGF: 28.47 )
GLPGF' s 10-Year ROE (%) Range
Min: -24.8   Max: 3.4
Current: 28.47

-24.8
3.4
ROA (%) 18.36
GLPGF's ROA (%) is ranked higher than
97% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. GLPGF: 18.36 )
GLPGF' s 10-Year ROA (%) Range
Min: -18.65   Max: 2.59
Current: 18.36

-18.65
2.59
ROC (Joel Greenblatt) (%) -133.84
GLPGF's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. GLPGF: -133.84 )
GLPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -141.5   Max: 6.71
Current: -133.84

-141.5
6.71
Revenue Growth (3Y)(%) -1.80
GLPGF's Revenue Growth (3Y)(%) is ranked higher than
76% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. GLPGF: -1.80 )
GLPGF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.8   Max: 42.3
Current: -1.8

-1.8
42.3
EPS Growth (3Y)(%) 110.50
GLPGF's EPS Growth (3Y)(%) is ranked higher than
99% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GLPGF: 110.50 )
GLPGF' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.5   Max: 110.5
Current: 110.5

-69.5
110.5
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
GLPGF's P/B is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. GLPGF: 2.60 )
GLPGF' s 10-Year P/B Range
Min: 0.61   Max: 4.25
Current: 2.6

0.61
4.25
P/S 3.05
GLPGF's P/S is ranked higher than
93% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. GLPGF: 3.05 )
GLPGF' s 10-Year P/S Range
Min: 0.87   Max: 8.21
Current: 3.05

0.87
8.21
EV-to-EBIT -26.81
GLPGF's EV-to-EBIT is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GLPGF: -26.81 )
GLPGF' s 10-Year EV-to-EBIT Range
Min: -21.8   Max: -0.6
Current: -26.81

-21.8
-0.6
Current Ratio 1.57
GLPGF's Current Ratio is ranked higher than
56% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. GLPGF: 1.57 )
GLPGF' s 10-Year Current Ratio Range
Min: 1.22   Max: 3.48
Current: 1.57

1.22
3.48
Quick Ratio 1.57
GLPGF's Quick Ratio is ranked higher than
58% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GLPGF: 1.57 )
GLPGF' s 10-Year Quick Ratio Range
Min: 1.22   Max: 3.45
Current: 1.57

1.22
3.45

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -3.70
GLPGF's Earnings Yield (Greenblatt) is ranked higher than
78% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. GLPGF: -3.70 )
GLPGF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -3.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, LSE:0Q4U, BIIB » details
Traded in other countries:0JXZ.UK, GLPG.Belgium, GLPG.Netherlands, GXE.Germany,
Galapagos NV was founded in 1999. It is an integrated drug discovery company with capabilities from target discovery to clinical proof of concept. The company operates in two business divisions, R&D and Services. It also offers contract research services in the areas of in vitro, biology, analytics, among others. R&D operations specialize in the discovery and development of small molecules. Service operations offer target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The Group's operations were located in Belgium, Croatia, France, Switzerland, The Netherlands and United Kingdom. The Group's R&D division is located in Belgium, Croatia, France and The Netherlands, with its service division operating in the remaining countries. Sales of goods consist of the sale of chemical compound libraries on a non-exclusive basis. The Group faces competition from contract research companies that may bring products and services to the market which are more competitive or affordable and which might hurt the position of the service operations.
» More Articles for GLPGF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Galapagos regains full rights to GPR84 inhibitor GLPG1205 Dec 16 2014
Galapagos increases share capital through warrant exercises Dec 10 2014
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA Nov 24 2014
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014 Nov 17 2014
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA Nov 12 2014
Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by... Oct 27 2014
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week Oct 20 2014
Galapagos creates new warrant plan Oct 20 2014
Bart Filius joins Galapagos as CFO Oct 15 2014
BUZZ-Galapagos at 6-mnth low on drug trial update Jun 17 2014
Galapagos to hold Annual R&D Update on 17 June 2014 in New York May 12 2014
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014 Apr 30 2014
Galapagos announces management change Apr 28 2014
Baker Brothers notify of 4.99% shareholding in Galapagos Apr 24 2014
Galapagos, GSK successfully conclude phase 2a study of skin disease drug Apr 17 2014
GSK2586184 met primary endpoint in Phase 2a psoriasis study Apr 17 2014
Galapagos raises €2.4 million through warrant exercises Apr 10 2014
Charles River Laboratories and Galapagos complete transaction Apr 01 2014
Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April... Mar 28 2014
Euronext Amsterdam to become Market of Reference for Galapagos Mar 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK